---
title: "Gilead And Lakefront Acquire Ouro Medicines In $1.67 Bln Agreement; To Co-Develop Gamgertamig"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288851463.md"
description: "Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines for $1.675 billion plus up to $500 million in milestones. The deal grants Gilead commercialization rights for Gamgertamig, a T-cell engager for autoimmune diseases, while Lakefront retains development responsibilities and royalty income. This transaction also resolves a prior licensing agreement, allowing Lakefront to acquire additional preclinical programs and boosting its cash reserves."
datetime: "2026-06-05T11:05:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288851463.md)
  - [en](https://longbridge.com/en/news/288851463.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288851463.md)
---

# Gilead And Lakefront Acquire Ouro Medicines In $1.67 Bln Agreement; To Co-Develop Gamgertamig

(RTTNews) - Gilead Sciences Inc. (GILD), a biopharmaceutical company, and Lakefront Biotherapeutics NV (LKFT), a biotechnology company, on Friday announced completing an acquisition of Ouro Medicines, and gaining a new portfolio of T-cell engager therapies to treat autoimmune diseases. According to the terms of the agreement, Gilead will acquire all outstanding equity of Ouro, amounting to $1.675 billion, and up to $500 million in milestone payments, with the upfront and milestone payments to be split between both Gilead and Lakefront.

The companies will acquire Ouro's lead asset of Gamgertamig (OM336), a clinical-stage BCMAxCD3 T-cell engager enabling rapid plasma and B-cell depletion to treat autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). The drug previously received Fast Track and Orphan Drug designation from the FDA.

With the deal, Lakefront acquired the operational assets of Ouro, and will advance ongoing and future Phase 1/2 development of gamgertamig. Gilead gains responsibility for registrational and later-stage studies, retaining sole commercialization rights for the drug. Accordingly, Lakefront is eligible to receive tired royalties of 20%-23% on net sales of gamgertamig from Gilead.

The companies previously signed a licensing agreement in 2019 to enable deployment of at least $500 million to Lakefront from Gilead. The Ouro transaction provides relief from this agreement, as Lakefront acquires a preclinical portfolio of three additional autoimmune focused programs, and may split profits from these with Gilead, amounting to up to $75 million per program. The acquisition will contribute to Lakefront's cash balance, which is estimated to reach $2 billion by the year end.

GILD closed Thursday at $129.18, up 0.15%. In the pre-market, shares are trading at $129.10, down 0.06%.

LKFT closed Thursday at $28.11, up 2.18%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline | GILD Stock News](https://longbridge.com/en/news/288769642.md)
- [Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa | GILD Stock News](https://longbridge.com/en/news/288820076.md)
- [Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome](https://longbridge.com/en/news/288463750.md)
- [Gilead Sciences, Inc. $GILD Shares Sold by BI Asset Management Fondsmaeglerselskab A S](https://longbridge.com/en/news/288924413.md)
- [Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial](https://longbridge.com/en/news/289224546.md)